These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34007169)

  • 1. Reply to: "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Letter].
    Barnes NC; Singh D; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1299-1301. PubMed ID: 34007169
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the Letter to the Editor Regarding "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Response to Letter].
    Lodise TP; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1227-1229. PubMed ID: 34007165
    [No Abstract]   [Full Text] [Related]  

  • 3. Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies.
    Lodise TP; Li J; Gandhi HN; O'Brien G; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2889-2900. PubMed ID: 33204085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study.
    Choi JH; Jeong KB; Park YH; Yu I; Lee SJ; Lee MK; Kim SH; Lee WY; Yong SJ; Lee JH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():3229-3237. PubMed ID: 34858023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.
    Janson C; Stratelis G; Miller-Larsson A; Harrison TW; Larsson K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3055-3064. PubMed ID: 29089754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
    Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACP Journal Club. Review: In COPD, fluticasone or budesonide increases serious pneumonia but not mortality.
    Stanbrook MB
    Ann Intern Med; 2014 Aug; 161(4):JC8. PubMed ID: 25133387
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies.
    Hollis S; Jorup C; Lythgoe D; Martensson G; Regnell P; Eckerwall G
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1071-1084. PubMed ID: 28435240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
    Halpin DM; Gray J; Edwards SJ; Morais J; Singh D
    Int J Clin Pract; 2011 Jul; 65(7):764-74. PubMed ID: 21676119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budesonide and risk of pneumonia.
    Kramer AB; Gans RO
    Lancet; 2009 Dec; 374(9707):2051. PubMed ID: 20109828
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide and risk of pneumonia.
    Black PN; Sexton PM
    Lancet; 2009 Dec; 374(9707):2050-2051. PubMed ID: 20109825
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data.
    Sin DD; Tashkin D; Zhang X; Radner F; Sjöbring U; Thorén A; Calverley PM; Rennard SI
    Lancet; 2009 Aug; 374(9691):712-9. PubMed ID: 19716963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.
    Wang CY; Lin YS; Wang YH; Lai CC; Wang HC; Chen L; Yu CJ;
    Aging (Albany NY); 2019 Sep; 11(17):6863-6871. PubMed ID: 31509517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
    Tashkin DP; Miravitlles M; Celli BR; Metzdorf N; Mueller A; Halpin DMG; Anzueto A
    Respir Res; 2018 Oct; 19(1):196. PubMed ID: 30290801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
    Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.